| Basics |
CorMedix Inc.
Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases.
|
| IPO Date: |
May 13, 2010 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$849.84M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.13 | 4.15%
|
| Avg Daily Range (30 D): |
$0.30 | 2.96%
|
| Avg Daily Range (90 D): |
$0.29 | 3.05%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
1.69M |
| Avg Daily Volume (90 D): |
1.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
237 |
| Avg Trade Size (Sh.) (30 D): |
113 |
| Avg Trade Size (Sh.) (90 D): |
103 |
| Institutional Trades |
| Total Inst.Trades: |
293 |
| Avg Inst. Trade: |
$1.4M |
| Avg Inst. Trade (30 D): |
$1.13M |
| Avg Inst. Trade (90 D): |
$1.14M |
| Avg Inst. Trade Volume: |
.16M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.57M |
| Avg Closing Trade (30 D): |
$1.31M |
| Avg Closing Trade (90 D): |
$1.22M |
| Avg Closing Volume: |
189.63K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$.26
|
$.32
|
$.24
|
|
Diluted EPS
|
$.24
|
$.3
|
$.24
|
|
Revenue
|
$ 82.55M
|
$ 39.08M
|
$ 31.21M
|
|
Gross Profit
|
$ 78.59M
|
$ 37.48M
|
$ 30.03M
|
|
Net Income / Loss
|
$ 17.18M
|
$ 20.64M
|
$ 13.46M
|
|
Operating Income / Loss
|
$ 14.47M
|
$ 20.13M
|
$ 12.94M
|
|
Cost of Revenue
|
$ 3.97M
|
$ 1.6M
|
$ 1.18M
|
|
Net Cash Flow
|
$ 31.03M
|
$ 25.63M
|
$ 5.36M
|
|
PE Ratio
|
50.54
|
|
|
|
